APA (7th ed.) Citation

Kim, S., Lee, S., Cho, J., Yoon, S. H., Jang, I., & Yu, K. (2017). Pharmacokinetics and tolerability of MB12066, a beta-lapachone derivative targeting NAD(P)H: Quinone oxidoreductase 1: two independent, double-blind, placebo-controlled, combined single and multiple ascending dose first-in-human clinical trials. Drug design, development and therapy, 11, 3187-3195. https://doi.org/10.2147/DDDT.S151269

Chicago Style (17th ed.) Citation

Kim, Seokuee, SeungHwan Lee, Joo-Youn Cho, Seo Hyun Yoon, In-Jin Jang, and Kyung-Sang Yu. "Pharmacokinetics and Tolerability of MB12066, a Beta-lapachone Derivative Targeting NAD(P)H: Quinone Oxidoreductase 1: Two Independent, Double-blind, Placebo-controlled, Combined Single and Multiple Ascending Dose First-in-human Clinical Trials." Drug Design, Development and Therapy 11 (2017): 3187-3195. https://doi.org/10.2147/DDDT.S151269.

MLA (9th ed.) Citation

Kim, Seokuee, et al. "Pharmacokinetics and Tolerability of MB12066, a Beta-lapachone Derivative Targeting NAD(P)H: Quinone Oxidoreductase 1: Two Independent, Double-blind, Placebo-controlled, Combined Single and Multiple Ascending Dose First-in-human Clinical Trials." Drug Design, Development and Therapy, vol. 11, 2017, pp. 3187-3195, https://doi.org/10.2147/DDDT.S151269.